TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15291291

Group type: EXPERIMENTAL
Intervention: Combat-related chronic PTSD (N=43)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combat-related chronic PTSD comorbid with alcohol dependence (N=41)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Healthy controls (N=39)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: PTSD group (N=43)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: PTSD comorbid with alcohol dependence (N=41)
Number of subjects: 123
Study: 11159760

Group type: EXPERIMENTAL
Intervention: 60 g meat/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 240 g meat/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 420 g meat/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0 g meat/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 420 g meat/day for 40 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Higher meat diets
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Longer transit times in the gut
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low faecal weight
Number of subjects: 8
Study: 10093071

Group type: EXPERIMENTAL
Intervention: 99Tcm‐ECD
Number of subjects: 11

Group type: COMPARATOR
Intervention: 99Tcm‐HMPAO
Number of subjects: 11
Study: 7697230

Group type: EXPERIMENTAL
Intervention: Fixed combination dry powder inhaler (Turbuhaler) containing terbutaline (250 micrograms) with budesonide (200 micrograms)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 74

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 74
Study: 2776952

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 901135

Group type: EXPERIMENTAL
Intervention: Ward environment perceived as lower in allowance of expression of anger and aggression, higher in order and organization (staff's perception)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ward environment perceived as homogeneous in outcome and assessments of order and organization and freedom to express anger and aggression
Number of subjects: 14
Study: 31861993

Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 26
Study: 27780334

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25599538

Group type: EXPERIMENTAL
Intervention: Femtosecond lenticule extraction (FLEx)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Small incision lenticule extraction (SMILE)
Number of subjects: 30
Study: 23820094

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Person-Centred Therapy (PCT)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Integrated CBT
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Single-focused CBT
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Therapist-delivered integrated CBT
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Computer-delivered integrated CBT
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Brief intervention (1 session)
Number of subjects: 303
Study: 21364502

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: uLMA
Number of subjects: 50
Study: 19334007

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention including passive movements/mobilizations, active movement/mobilizations, home exercise programme, education and advice, and ultrasound.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 98
Study: 17093161

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Iron-folate supplementation (control)
Number of subjects: 70
Study: 15017802

Group type: EXPERIMENTAL
Intervention: Tractors operated by children
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Tractors of at least 20 horsepower operated by children
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Tractors equipped with ROPS
Number of subjects: 1113
Study: 11696921

Group type: EXPERIMENTAL
Intervention: SRP + irrigation with collagen gel containing 1% chlorhexidine (group 3)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SRP + irrigation with collagen gel (group 2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: SRP only (group 1)
Number of subjects: 6
Study: 9440363

Group type: EXPERIMENTAL
Intervention: Previous trial involved a nonword
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous trial involved a nonword or pseudohomophone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous trial involved a word
Number of subjects: 0
Study: 8535199

Group type: EXPERIMENTAL
Intervention: RCM protocol: response-oriented cyclic multidrug protocol
Number of subjects: 43
Study: 2691317

Group type: EXPERIMENTAL
Intervention: Shosaiko-to (SST) 5.4 g daily for 12 weeks
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo 0.5 g of SST for 12 weeks
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Shosaiko-to (SST) after crossover from placebo
Number of subjects: 222
Study: 30052924

Group type: EXPERIMENTAL
Intervention: Community-based exercise program with motivational interviewing
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual PA recommendations
Number of subjects: 69
Study: 28845695

Group type: EXPERIMENTAL
Intervention: 24-week Tai Chi intervention
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 48-week Tai Chi intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 26955704

Group type: EXPERIMENTAL
Intervention: Esmolol infusion (0.05 mg · kg(‐1) · min(‐1) for 24 hours)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 48
Study: 22674544

Group type: EXPERIMENTAL
Intervention: Continuous stimulation (CS, n = 10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Discontinuous nonperiodic stimulation (DnPS, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Discontinuous periodic stimulation (DPS, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Absent stimulation (AbS, n = 10)
Number of subjects: 40
Study: 23198465

Group type: EXPERIMENTAL
Intervention: Open-sandwich technique using Ketac Molar set with ultrasound (US)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Filtek Z250 (control group)
Number of subjects: 100
Study: 19614947

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 267

Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 267
Study: 16791109

Group type: EXPERIMENTAL
Intervention: Levosimendan 0.2 microg/kg/min
Number of subjects: 35
Study: 15199073

Group type: EXPERIMENTAL
Intervention: telavancin 7.5 mg/kg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: telavancin 15 mg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: moxifloxacin 400 mg (positive control)
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study: 11255588

Group type: EXPERIMENTAL
Intervention: Simple dissemination method
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Intensive dissemination method
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both dissemination methods
Number of subjects: 223

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 223
Study: 9291289

Group type: EXPERIMENTAL
Intervention: native phospholipase A2 (nPLA)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: recombinant phospholipase A2 (rPLA)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: specific serum IgE to BV
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: specific serum IgE to nPLA
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: specific serum IgE to rPLA
Number of subjects: 85
Study: 8286162

Group type: EXPERIMENTAL
Intervention: Parents receiving a copy of the letter from the paediatrician to the GP
Number of subjects: 89

Group type: COMPARATOR
Intervention: Parents not receiving a copy of the letter from the paediatrician to the GP (comparison group)
Number of subjects: 89
Study: 2886533

Group type: EXPERIMENTAL
Intervention: Latamoxef at 6 g day‐1
Number of subjects: 102

Group type: COMPARATOR
Intervention: Latamoxef at 3 g day‐1
Number of subjects: 102
Study: 31841687

Group type: EXPERIMENTAL
Intervention: PBM-T
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PBM-T + PDT
Number of subjects: 56
Study: 30140929

Group type: EXPERIMENTAL
Intervention: Traditional Microscopy (TM)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Whole-Slide Imaging (WSI)
Number of subjects: 87
Study: 28634649

Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day)
Number of subjects: 0
Study: 25439435

Group type: EXPERIMENTAL
Intervention: AKB‐9778 15 mg or more twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AKB‐9778 22.5 mg or more twice daily
Number of subjects: 24
Study: 23972322

Group type: EXPERIMENTAL
Intervention: Antioxidants alone
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Zinc and antioxidants
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Zinc-containing regimens
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Any category of AREDS treatment
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Zinc-only supplementation
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Antioxidant-only supplementation
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 995
Study: 21225699

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg on days 1 and 15)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Presence of anti‐CCP antibodies or RF
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Serum IgG concentration above normal
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Presence of RF or anti‐CCP antibodies and elevated IgG
Number of subjects: 208
Study: 19006481

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 0
Study: 16543538

Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training (4 weeks, supervised)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed intervention (no training during weeks 3-6)
Number of subjects: 16
Study: 13129638

Group type: EXPERIMENTAL
Intervention: 0.526 U I-125 seeds
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.414 U I-125 seeds
Number of subjects: 20
Study: 10753248

Group type: EXPERIMENTAL
Intervention: Spacer group (albuterol 600 microg by MDI with spacer)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nebulizer group (2.5 mg albuterol by nebulizer)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spacer group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nebulizer group
Number of subjects: 60
Study: 8884922

Group type: EXPERIMENTAL
Intervention: Oral intake of CoQ10
Number of subjects: 31
Study: 1362841

Group type: EXPERIMENTAL
Intervention: Dithranol 2% ointment applied once daily for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo ointment applied once daily for 8 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dithranol treatment
Number of subjects: 27
Study: 6385701

Group type: EXPERIMENTAL
Intervention: Bovine heparin
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Porcine heparin
Number of subjects: 141

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 141
Study: 30958051

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 15°C for 15 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Phase Change Material (PCM) at 15°C for 3 h
Number of subjects: 11
Study: 29782641

Group type: EXPERIMENTAL
Intervention: Epidural oxycodone 0.1 mg·kg-1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous oxycodone 0.1 mg·kg-1
Number of subjects: 30
Study: 26838142

Group type: EXPERIMENTAL
Intervention: Mango-flavored candy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Milk chocolate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fruit and nuts chocolate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All chocolates assessed
Number of subjects: 30
Study: 25106506

Group type: COMPARATOR
Intervention: Letter reminder (CONTROL)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Telephone reminder (TEL)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Telephone reminder plus telephone support (TEL-SUPP)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Telephone reminder plus support plus anticipated regret (TEL-SUPP-AR)
Number of subjects: 600
Study: 23137512

Group type: EXPERIMENTAL
Intervention: NT-proBNP guided care aiming to reduce NT-proBNP values ≤1000 pg/mL
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) HF management
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: NT-proBNP guided care
Number of subjects: 151
Study: 20381658

Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin (HbA(1c)) assessment during hospitalization or documented in the chart from the preceding 3 months
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Good control of HbA(1c) (<7%)
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Suboptimal control of HbA(1c) (7% to 9%)
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Poor control of HbA(1c) (>9%)
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: DM treatment intensification for suboptimal control (HbA(1c) 7% to 9%)
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: DM treatment intensification for poor control (HbA(1c) >9%)
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Instructions on DM disease management before discharge
Number of subjects: 1168
Study: 18431346

Group type: EXPERIMENTAL
Intervention: MC-1 250 mg/day
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: MC-1 750 mg/day
Number of subjects: 901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study: 15896928

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study: 11874394

Group type: EXPERIMENTAL
Intervention: CNS 5161
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10637702

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreatoduodenectomy (PPPD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Duodenopancreatectomy (PD)
Number of subjects: 48
Study: 7737776

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 3 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Terbinafine 250 mg for 3 months
Number of subjects: 53
Study: 2044924

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.1N hydrochloric acid infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Autologous duodenal secretions infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall response to acid and/or bile
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Negative response group
Number of subjects: 18
Study: 6291739

Group type: EXPERIMENTAL
Intervention: Daily radiotherapy (5000 rad in 25 fractions in 5 weeks)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Q3h Cobalt 60 irradiation (3600‐4000 rad in 36‐40 fractions of 100 rad each, given 4 fractions per day at 3‐hour intervals over two weeks)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both treatment groups (hyperfractionation and daily regimens)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Hyperfractionation with chemotherapy
Number of subjects: 157
Study: 31305505

Group type: EXPERIMENTAL
Intervention: Subretinal hyperreflective material (SHRM) with layered appearance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subretinal hyperreflective material (SHRM) with hyperreflective spots
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separation between SHRM and outer retina
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disappearance of SHRM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Layered appearance of SHRM at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreasing reflectivity of SHRM lesion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased width and area of baseline SHRM at the foveal center
Number of subjects: 0
Study: 30936690

Group type: EXPERIMENTAL
Intervention: Moderate altitude exposure (2,590 m)
Number of subjects: 37
Study: 28296779

Group type: EXPERIMENTAL
Intervention: Fresh packed red blood cells (RBCs) stored less than 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer-storage packed red blood cells (RBCs) stored more than 10 days but less than 35 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no transfusion)
Number of subjects: 0
Study: 25616431

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axitinib (in patients with prior cytokine-containing regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axitinib (in patients with prior sunitinib treatment)
Number of subjects: 0
Study: 25453119

Group type: EXPERIMENTAL
Intervention: Parecoxib plus phloroglucinol
Number of subjects: 236

Group type: COMPARATOR
Intervention: Parecoxib plus placebo
Number of subjects: 236
Study: 21111681

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tribendimidine
Number of subjects: 125
Study: 19608833

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (end-tidal 1.5%-2%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Desflurane anesthesia (end-tidal 6%-7%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 17372669

Group type: EXPERIMENTAL
Intervention: Components Separation Technique (CST)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Prosthetic Repair (PR)
Number of subjects: 39
Study: 15964483

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine at 10 microg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine at 25 microg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine at 50 microg
Number of subjects: 2
Study: 11796658

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (Cr, 4 x 5 g/day, 4 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (Caf, 5 mg x kg(‐1) x day(‐1), 3 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Creatine + Caffeine supplementation (Cr+Caf)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute caffeine intake (ACaf, 5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10752310

Group type: EXPERIMENTAL
Intervention: Subthreshold transcranial magnetic stimulation (TMS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no TMS)
Number of subjects: 7
Study: 8648453

Group type: EXPERIMENTAL
Intervention: Earmuffs reducing noise intensity by 7 to 12 dB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual noise in the NICU
Number of subjects: 30
Study: 2404843

Group type: EXPERIMENTAL
Intervention: Carboplatin administered at 06.00
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin administered at 18.00
Number of subjects: 0
Study: 7298477

Group type: EXPERIMENTAL
Intervention: Therapies (specific types not detailed)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation
Number of subjects: 264

Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 264
Study: 31197861

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Oral ferrous sulphate (FeSulf)
Number of subjects: 61
Study: 28982527

Group type: EXPERIMENTAL
Intervention: Text4baby and Quit4baby (intervention)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Text4baby (control)
Number of subjects: 497
Study: 25946691

Group type: COMPARATOR
Intervention: Classic inverted ILM flap technique
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Temporal inverted ILM flap technique
Number of subjects: 87
Study: 22633446

Group type: EXPERIMENTAL
Intervention: SM-fortified milk (SM 20% of all phospholipids in milk)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (SM 13% of all phospholipids in milk)
Number of subjects: 24
Study: 21640762

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg per day (AT group, n=52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LM group, n=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Healthy controls (HC group, n=40)
Number of subjects: 104
Study: 20001838

Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique (NET) - two 30-minute sessions approximately 2 weeks apart
Number of subjects: 15

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 15
Study: 17195236

Group type: EXPERIMENTAL
Intervention: CAT-192 (10 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CAT-192 (5 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CAT-192 (0.5 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CAT-192 (all doses)
Number of subjects: 45
Study: 12686786

Group type: EXPERIMENTAL
Intervention: 1 mg/h nimodipine
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 2 mg/h nimodipine
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: High-dose nimodipine
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Nimodipine treatment
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Systolic BP reduction
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Diastolic BP reduction
Number of subjects: 295
Study: 10985616

Group type: EXPERIMENTAL
Intervention: Cetrorelix (LHRH antagonist)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Buserelin (LHRH agonist)
Number of subjects: 273